PT-141 is a synthetic peptide hormone developed by Palatin Technologies and approved by the FDA in 2019 as a treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first and only FDA-approved medication for this condition, which is characterized by low libido and an absence of sexual fantasies and desire for sexual activity.
PT-141 works by activating the melanocortin receptors in the brain, which are responsible for sexual arousal and desire. When PT-141 binds to these receptors, it causes a cascade of neurochemical effects that enhance libido and sexual motivation. Some key effects of PT-141 include:
PT-141 is administered as a nasal spray that is taken prior to anticipated sexual activity. Effects are noticed within 2 hours and peak at around 6 hours, lasting for up to 24 hours. In clinical trials, PT-141 increased sexual desire, arousal, fantasies, orgasms, and satisfaction in women with HSDD.
Some potential side effects may include facial flushing, nausea, headache, and changes in taste perception. It should not be taken with alcohol or certain medications like blood pressure drugs. Those with heart conditions or on blood thinners should exercise caution with PT-141.
While not a cure, PT-141 provides much needed relief for women struggling with sexual dysfunction. It empowers them to reclaim their sexuality and enjoy intimate relationships again.
If you are experiencing low libido or lack of desire, consider making an appointment with the hormone experts at Rejuvenate Medical_. We offer cutting edge bioidentical hormone therapies and medications like_ PT-141 to help you regain your passionate side. Our compassionate providers will get to the root cause and craft a personalized treatment plan just for you. Rediscover intimacy and revitalize your relationships with help from Rejuvenate Medical today!